Key Highlights

  • Aytu BioPharma (NASDAQ:AYTU) was trading up 46.15% at USD 2.66 on Tuesday, November 17, 2026, about 1.5% below the USD 2.70 a share cash offer from Rosemont Pharmaceuticals Holdings (calculated).
  • Rosemont values the deal at about USD 56 million on a fully diluted basis, and published coverage puts the offer at a 51.7% premium to the November 13 close and 41.1% above the 30-day volume-weighted average price.
  • Closing is targeted for late December 2026 and needs a majority of shares tendered; published coverage says either side can end the deal if it has not closed by February 14, 2027, with a USD 2.4 million termination fee in some cases.
  • Fiscal first-quarter Revenue was USD 14.8 million against USD 13.9 million a year earlier, with a net loss of USD 3.9 million, cash of USD 25.5 million and ADHD portfolio revenue down to USD 7.7 million from USD 13.2 million.

A USD 2.70 Cash Tender Offer Resets the Share Price

Aytu BioPharma (NASDAQ:AYTU) was trading up 46.15% at USD 2.66 on Tuesday, November 17, 2026. The move follows a November 16, 2026 announcement that Rosemont Pharmaceuticals Holdings agreed to acquire the company for USD 2.70 a share in cash, about USD 56 million on a fully diluted basis using the treasury stock method. The screener move implies a prior close near USD 1.82, while published coverage measures the 51.7% premium from the November 13 close, so the two bases differ slightly. Aytu sells prescription medicines for the central nervous system and pediatric markets, including EXXUA for major depressive disorder and ADHD treatments.

How the Two-Step Deal Works and What Must Happen Before Closing

The structure is a tender offer followed by a merger. Rosemont's Acquisition Subsidiary must file a Schedule TO with the SEC and launch the offer, which published coverage says is due within 10 Business days of signing and open for 20 days unless extended. Aytu BioPharma (NASDAQ:AYTU) will file a Schedule 14D-9 with its board's recommendation. The release lists a majority of outstanding shares tendered as a condition, and published coverage adds that no more than 15% of warrants, by underlying shares, may remain unexercised and untendered. Shares not tendered would convert into the same cash through a Delaware Merger without a further vote. The company expects closing by the end of calendar 2026.

Fiscal First-Quarter Numbers, the ADHD Decline and Deal Risks

The company reported fiscal 2027 first-quarter results on November 16, 2026. Revenue was USD 14.8 million versus USD 13.9 million, the net loss was USD 3.9 million and adjusted EBITDA was a loss of USD 2.6 million versus a loss of USD 0.6 million. Cash was USD 25.5 million, against about USD 16.5 million of Debt (calculated from the revolver and term debt). ADHD portfolio revenue fell to USD 7.7 million from USD 13.2 million, while EXXUA contributed USD 4.9 million. Published coverage says officers, directors and affiliates of Nantahala Capital Management and Stonepine Capital Management agreed to tender, though their combined stake was not disclosed; that is single-source. Risks include a failed condition or a delay past February 14, 2027.

Where Things Stand

The jump reflects a cash Takeover offer, not an operating rebound. Aytu BioPharma (NASDAQ:AYTU) trades about 1.5% below the USD 2.70 offer (calculated), a gap that usually reflects time and completion risk. Rosemont's tender launch, the board recommendation filing, the share count tendered and any regulatory or Warrant conditions are the next markers, with closing targeted for late December 2026. A small number of trades can move the price and quoted moves can reverse if terms change.